Pharmaceuticals
IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment
SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 30, 2024 /PRNewswire/ -- OnSeptember 23, in Rio de Janeiro, on the eve of the International Myeloma Society (IMS) Annual Meeting, Dr.Yongke Zhang, Chief Scientific Officer of IASO Biotherapeutics (IASO Bio), along with leading Chinese onco-h...
2024-09-30 13:48
1001
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
HONG KONG, Sept. 30, 2024 /PRNewswire/ -- September 30, 2024, Akeso (9926. HK) announced that its internally developed PD-1/CTLA-4 bispecific antibody, cadonilimab, has received approval from the National Medical Products Administration (NMPA) for a new indication: cadonilimab in combination with...
2024-09-30 13:42
990
Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer
* Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of$850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire...
2024-09-30 13:00
925
Alphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China
SUZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of Alphamab Oncology ("the Company"), entered into a licensing agreement (the "Licensing Agreement") on anti-H...
2024-09-30 10:35
3235
SeromYx Systems and ACROBiosystems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies
NEWARK, Del., Sept. 29, 2024 /PRNewswire/ -- SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, an innovative provider for life science solutions and tools, are excited to announce the release of their joint study on the comprehensive functional profiling of approv...
2024-09-29 21:00
1269
IASO Bio Presented Comparative Clinical Outcomes on the Optimal Lymphodepletion Prior to Infution of Equecabtagene Autoleucel（FucasoTM）in Patients with Relapsed Refractory Multiple Myeloma at 2024 IMS Annual Meeting
SHANGHAI and NANJING, China and SAN JOSE, Calif, Sept. 29, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentati...
2024-09-29 21:00
2210
Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress
CHENGDU, China, Sept. 29, 2024 /PRNewswire/ -- From September 25th to 29th, the 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting were held inXiamen. Experts and scholars in the field of oncology from all over China gathered together to discuss the hotspots at the forefront o...
2024-09-29 11:52
2549
New Beginnings, New Journey | Sanyou Opening of New 10,000-sqm Facility, Ushering in a New Era of Innovation for Bio Drugs
SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Sanyou Bio recently celebrated a prestigious move into its new 10,000-square-meter R&D building atShanghai headquarters. This is not just a change in physical location, but a qualitative leap in the company infrastructure. It marks a solid step forward for...
2024-09-28 20:00
2938
Frost & Sullivan Released Report: "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends"
SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Frost & Sullivan released the "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" which focus on the progress of Chinese biopharmaceuticals going global and analyzes the driving forces behind their accelerated global expa...
2024-09-28 09:11
3257
111, Inc. Announces Receipt of Notification from Nasdaq
SHANGHAI, Sept. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced it has received a...
2024-09-28 05:00
2905
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
GAITHERSBURG, Md., Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
2024-09-27 19:00
1493
Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer
TAIPEI, Sept. 27, 2024 /PRNewswire/ -- Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, in patients with mismatch repair–proficient (pMMR) or mi...
2024-09-27 16:00
1549
IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting
SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 27, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentat...
2024-09-27 15:41
1095
ArkBio Announces Publication of Phase 3 Clinical Trial Results of Ziresovir for the Treatment of RSV Infection in The New England Journal of Medicine
SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a clinical stage biopharmaceutical company focused on the development of therapeutics in respiratory, infectious and pediatric diseases, announced that the results of the phase 3 clinical trial of zireso...
2024-09-26 20:28
1832
Breakthrough Therapy Designation (BTD) for BioCity's SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria
SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 has been granted the Breakthrough Therapy Designation (BTD) by National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN...
2024-09-26 15:10
1396
Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis
SAN FRANCISCO and SUZHOU, China, Sept. 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2024-09-26 12:15
1866
The World First Liquid Formulation of Recombinant Botulinum Toxin Type A Has Obtained IND Approval by the FDA
CHONGQING, China, Sept. 25, 2024 /PRNewswire/ -- MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially owned subsidiary, Claruvis Pharmaceutical Co., has received approval from the U.S. Food and Drug A...
2024-09-25 21:18
1773
Rx-360 Announces Approval as a Pilot Center of Excellence for the APEC Regulatory Harmonization Steering Committee
PHILADELPHIA, Sept. 25, 2024 /PRNewswire/ -- Rx-360® is pleased to announce that it has been accepted as a Pilot Center of Excellence (CoE) for the APEC Regulatory Harmonization Steering Committee. The pilot will be focused on the Global Medical Product Supply Chain Integrity Priority Work Area R...
2024-09-25 21:09
1566
Samsung Biologics launches development platforms for enhanced therapeutic efficacy
* Samsung Biologics showcases new innovative development platforms – S-AfuCHO TM and S-OptiChargeTM – at BioProcess International 2024 * New technology platforms to proactively address evolving industry trends and enable high-quality development INCHEON, South Korea, Sept. 25, 2024 /PRNewswire...
2024-09-25 19:00
1302
GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia
* Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV * Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy observed in adults with co-morbidities vii KUALA LUMPUR, Malaysia, Sept. 25, 2024 /PRNewswire...
2024-09-25 16:45
1799
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6494
